Impact of human papillomavirus vaccination depends on effective vaccination strategy

International Journal of Cancer

Volumn 125, Issue 6, 2009, Pages 1490-1491

  Lehtinen, Matti ^a,b   Paavonen, Jorma ^c  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^b TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

MEASLES MUMPS RUBELLA VACCINE; RUBELLA VACCINE; WART VIRUS VACCINE;

CANCER RISK; CANCER SCREENING; DRUG EFFICACY; EPIDEMIC; HEALTH CARE; HEALTH PRACTITIONER; HUMAN; INTRAUTERINE INFECTION; LETTER; MEASLES; MUMPS; PREGNANCY; PRIORITY JOURNAL; RUBELLA; UTERINE CERVIX CANCER; VACCINATION; VERRUCA VULGARIS; VIRUS TRANSMISSION; WART VIRUS;

HUMANS; MASS SCREENING; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; VACCINATION;

EID: 68249145971     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24476     Document Type: Letter

References (16)

1. Ojala P, Elo O, Vesikari T. Rubella during pregnancy as a cause of congenital hearing loss. Am J Epidemiol 1973;98:395-401.
2. Vaheri A, Vesikari T, Oker-Blom N, Seppala M, Parkman PD, Veronelli J, Robbins FC. Isolation of attenuated rubella vaccine virus from human products of conception and uterine cervix. N Engl J Med 1972;286:1071-4.
3. www.stakes.fi.
4. Peltola H, Jokinen S, Paunio M, Hovi T, Davidkin I. Measles, mumps and rubella in Finland: 25 years of a nationwide elimination programme. Lancet Infect Dis 2008;8:796-803.
5. Garnett G. Inferring mechanisms of sexual partnership formation from the distribution of sexual partner numbers. Sex Transm Dis 2008;35:41-2.
6. Barnabas R, Laukkanen P, Koskela P, Kontula O, Lehtinen M, Garnett G. The epidemiology of HPV16 and cervical cancer in Finland and the potential of vaccination: mathematical modelling analyses. PLoS Med 2006;3:e138.
7. Lehtinen M, French K, Dillner J, Paavonen J, Garnett G. Sound implementation of HPV vaccination. Future Med (Therapy) 2008;5: 289-94.
8. French KM, Barnabas R, Lehtinen M, Kontula O, Pukkala E, Dillner J, Garnett GP. The impact of lowering the age of HPV vaccination and other vaccination strategies. Br J Cancer 2007;96:514-18.
9. Goldhaber-Flebert JD, Stout NK, Salomon JA, Kuntz KM, Goldie SJ. Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16/18 vaccination. J Natl Cancer Inst 2000;100:308-20.
10. Kalliala I, Anttila A, Pukkala E, Nieminen P. Risk of cervical and other cancers after treatment of cervical intraepithelial neoplasia. BMJ 2005;331:1183-5.
11. Lehtinen M, Kaasila M, Pasanen K, Patama T, Palmroth J, Laukkanen P, Pukkala E, Koskela P. Seroprevalence ATLAS of HPV infections in Finland. Int J Cancer 2006;120:2612-19.
12. Bray F, Loos AH, McCarron P, Weiderpass E, Arbyn M, Møller H, Hakama M, Parkin DM. Trends in cervical squamous cell carcinoma incidence in 13 European countries. Cancer Epidemiol Biomarkers Prev 2005;14:677-86.
13. Brabin L, Roberts SA, Stretch R, Baxter D, Chambers G, Kitchener H, McCann R. Uptake of first two doses of human papillomavirus vaccine by adolescent schoolgirls in Manchester. BMJ 2008;336: 1056-8.
14. Lehtinen M, Herrero R, Mayaud P, Barnabas R, Dillner J, Paavonen J, Smith PG. Studies to assess long-term efficacy and effectiveness of HPV vaccination in developed and in developing countries. Vaccine 2006;24:S233-41.
15. Kim JJ. Human papillomavirus vaccination in the UK. BMJ 2008; 337:a842.
16. Jit M, Hong Choi Y, Edmunds WJ. Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ 2008;337: a769.